Apollomics highlights clinical progress and reports full year 2023 financial results

Foster city, calif., march 28, 2024 (globe newswire) --  apollomics inc. (nasdaq: aplm) (“apollomics” or the “company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended december 31, 2023, and highlighted progress of its pipeline.
APLM Ratings Summary
APLM Quant Ranking